Overview of Codin P

Property	Description
Active ingredient	Chlorpheniramine Maleate (INN)
Form	Oral Solid Dosage Form (Tablet)
Pharmacological class	First-Generation Antihistamine
General purpose	Symptomatic relief of allergic reactions
Origin	Synthetic

What is Codin P and What Type of Medicine Is It?

Codin P is a systemic pharmaceutical composition whose active ingredient is the synthetic compound, Chlorpheniramine Maleate. It is classified as a first-generation antihistamine, a chemical subgroup of substituted alkylamines. Its therapeutic action follows an established mechanism: functioning as a competitive antagonist at the Histamine H₁ receptors throughout the body. Unlike many contemporary analogues, this agent is specifically a sedating antihistamine.

Chlorpheniramine Maleate: Composition and Origin

The product is a single-ingredient preparation of synthetic origin, administered via the oral route as an oral solid dosage form (a tablet). The therapeutic effect is delivered by Chlorpheniramine Maleate, which is chemically structured as a Maleate salt to optimize the compound's stability and solubility for reliable systemic absorption. The compound has a long history of use in clinical practice, which characterizes its profile as a core antihistamine.

What is the General Purpose of This Antihistamine?

The general purpose of Codin P is to provide symptomatic relief by mitigating the effects of histamine, the body's primary chemical released during allergic responses. By engaging in Histamine Blockade, the medicine works to reduce the common physiological reactions that define an allergic response, such as persistent sneezing, itching, or a runny nose. This action is systemic, offering general symptomatic comfort associated with acute, temporary allergic manifestations.

Regulatory References

NIH MedlinePlus on Chlorpheniramine

What side effects are possible with Codin P?

Possible Side Effects and Safety Information

The safety profile for Codin P, which contains Chlorpheniramine Maleate, is defined by effects on the central nervous system and its anticholinergic properties, as documented in official regulatory sources.

Frequency-Classified Adverse Reactions

The most frequently reported effects are related to the compound's sedative nature:

Very Common Reactions: These are reactions cited as occurring in one or more out of ten patients in some clinical data, including sedation and somnolence (drowsiness).
Common Reactions: These effects, noted in up to 10% of patients in certain regulatory documents, include dizziness, headache, dry mouth, nausea, fatigue, and blurred vision.

System-Organ-Class Safety Overview

Adverse reactions are organized by the System Organ Class (SOC) affected. The Nervous System is commonly involved, along with Gastrointestinal Disorders and Eye Disorders. Less common but officially documented effects fall under Vascular and Cardiac Disorders (e.g., hypotension, arrhythmias) and Blood and Lymphatic System Disorders (e.g., blood dyscrasias).

Serious Adverse Reactions and Contextual Safety

Official labels document potential for serious adverse outcomes, albeit at an unknown frequency, such as anaphylactic reactions and convulsions.

Population-Specific Notes: Regulatory documents specify that children and the elderly may be more susceptible to anticholinergic effects, including paradoxical excitation (restlessness). Caution is specifically advised for patients with pre-existing hepatic and renal impairment.

Safety Restrictions: Due to the risk of exacerbating symptoms, the medicine is contraindicated in conditions such as narrow-angle glaucoma, urinary retention, and pyloroduodenal obstruction.

Overdose and Emergency Response

The official regulatory profile for a Chlorpheniramine Maleate overdose is characterized by severe central nervous system (CNS) and anticholinergic toxicity. Documented manifestations include a progression from CNS depression, such as deep sedation or coma, to paradoxical CNS excitation, characterized by agitation, restlessness, convulsions, and toxic psychosis. Physical signs of toxicity include mydriasis (dilated pupils), hyperpyrexia, and urinary retention.

Overdose can lead to life-threatening outcomes, specifically documented as cardiovascular collapse, severe cardiac arrhythmias, apnoea, and respiratory failure. Immediate medical advice must be sought in the event of any suspected overdose, even if the individual appears to be asymptomatic.

Urgent medical attention is required for the treatment of severe or life-threatening symptoms. The official management is exclusively symptomatic and supportive, as regulatory documents state that no specific antidote is known. Procedures may include considering activated charcoal for recent oral ingestion and the vigorous treatment of complications like hypotension. Regulatory information highlights that children and the elderly are noted to be more susceptible to paradoxical neurological excitation.

Therapeutic Uses of Codin P

What Codin P Treats: Main Uses and Benefits

Codin P is a medication that plays a role in managing symptoms related to heightened physiological activity caused by allergic reactions. Its primary use is to provide supportive relief for symptoms associated with allergies, hay fever, and the common cold.

The medication is commonly used across conditions presenting with systemic or localized discomfort. Indications relevant for symptomatic management include allergic rhinitis, allergic conjunctivitis, and urticaria (hives). It is applied in clinical settings that involve acute or unstable symptom patterns, such as sudden allergic flares or the symptomatic onset of a common cold.

“It is relevant when short-term symptomatic assistance is needed to manage a temporary escalation of symptoms that interfere with daily functioning.”

This supportive relief contributes to easing the overall symptom burden during periods of heightened distress, and assists with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Supports management of Nasal and Ocular Irritation

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Codin P?

This medicine's eligibility is strictly defined by regulatory bodies to protect populations at high risk for serious adverse effects, primarily life-threatening respiratory depression.

Absolute Contraindications

Codin P (Codeine Phosphate/Sulfate) must not be used in the following populations, as stated in official government labeling:

Children younger than 12 years of age.
All pediatric patients (0-18 years) following tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome.
Women who are breastfeeding.
Patients of any age known to be CYP2D6 ultra-rapid metabolisers, a genetic status that results in rapid, excessive conversion of codeine to morphine.
Patients with significant respiratory depression or acute/severe bronchial asthma.
Patients with a known or suspected gastrointestinal obstruction, including paralytic ileus.
Patients with severe hepatic dysfunction or hepatic failure.

Populations Requiring Restricted or Conditional Use

Use is not recommended or requires strict caution and dose adjustment in the following groups:

Adolescents 12 to 18 years of age with certain risk factors (e.g., severe lung disease or obesity).
Elderly patients (caution and a lower dose required).
Patients with hepatic or renal impairment (dose adjustment required).
Use during pregnancy is generally not recommended and carries the risk of Neonatal Opioid Withdrawal Syndrome.

What should I know about interactions with other medicines?

Codin P interactions are officially documented across several categories, primarily involving pharmacodynamic reinforcement and a mandatory pharmacokinetic constraint.

Prohibited Combinations and Timing Rules

The co-administration of Codin P is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including all therapeutic MAOIs. This restriction is also mandatory for a period of fourteen days following the discontinuation of any MAOI therapy, establishing a required separation window. This constraint is documented to prevent the intensification of sedative and anticholinergic effects.

Pharmacodynamic Effects

Co-administration with other Central Nervous System (CNS) Depressants (such as opioid analgesics, hypnotics, and sedatives) is associated with an additive CNS depressant effect, potentially resulting in increased sedation. Similarly, taking Codin P concurrently with Anticholinergic Drugs (including tricyclic antidepressants) may result in an enhancement of anticholinergic effects. Furthermore, regulatory information notes that consuming Alcohol with this medicine is documented to enhance the sedative effects.

Pharmacokinetic Interaction

A specific pharmacokinetic interaction is documented with Phenytoin. Codin P is known to inhibits the hepatic metabolism of Phenytoin, which creates an officially recognized risk of Phenytoin accumulation and toxicity due to increased plasma concentration.

Mechanism of Action

Codeine is an opioid prodrug that undergoes metabolic activation in the liver via O-demethylation to form the active metabolite, morphine. This conversion is primarily catalyzed by the cytochrome P450 2D6 (CYP2D6) isoenzyme.

Morphine functions as an agonist at central nervous system mu-opioid receptors (mu-OR). Binding to mu-OR, a G-protein coupled receptor (GPCR), inhibits adenylyl cyclase activity, leading to a decrease in intracellular cyclic AMP (cAMP). This cellular effect causes neuronal hyperpolarization by altering potassium and calcium ion fluxes. The resulting cascade modulates the presynaptic release of key nociceptive neurotransmitters, thereby affecting the transmission of pain signals.

Codeine itself and its metabolites also interact with opioid receptors in the medulla, specifically affecting the neuronal activity in the cough reflex pathway. This action involves mu-OR agonism, which is associated with modulation of ion channel function, raising the threshold for cough initiation.

Dosage and Administration Information

How to Use Codin P

Codin P is an oral solid dosage form of Chlorpheniramine Maleate administered for symptomatic relief. The drug's usage is characterized by a specific dosing schedule, short-term duration, and necessary adjustments for certain populations. The medicine is classified for oral administration and should be swallowed whole with water; it can be taken with or without food.

Official Dosing and Frequency

Usage follows an intermittent, as-needed schedule. The standard dose is 4 mg, repeated every 4 to 6 hours while symptoms are present.

Age Group	Standard Dose	Maximum Daily Dose
Adults ge 12 Years	4 mg per dose	24 mg (6 tablets)
Children 6 to under 12 Years	2 mg per dose	12 mg (3 tablets)

Usage Constraints and Adjustments

Standard guidelines indicate that use is typically short-term, and the duration should not generally exceed seven days without consulting a practitioner. Furthermore, a reduced daily dose, such as 4 mg once or twice daily with a lower total daily maximum, is typically followed for older adults.

Recent Clinical Evidence

Codin P: Recent Clinical Evidence

The following overview describes the scope and findings reported in clinical trials and published research that investigated this drug. This summary strictly reflects the reported study endpoints and does not provide any medical advice or recommendations.

Biological Activity and Initial Trials

The primary research program included studies to investigate the drug’s potential biological activity. These initial laboratory-based studies were conducted prior to the clinical research program.

Phase 2 and 3 Clinical Trials

Studies investigated the drug’s use in chronic conditions. The primary endpoint for these trials was the change in a validated symptom score over a six-week period.

Reported Changes in Mood: These studies recorded a difference in mood scores in approximately 60% of participants. Further research, including post-market studies, is investigating the long-term findings related to these reported changes.
Symptom Management: Research examined the data related to changes in patient-reported pain and anxiety symptom scores. This evaluation was generally conducted using patient-reported outcome measures (PROMs).

Pharmacokinetic Investigations

Studies investigated the drug’s pharmacokinetic profile in both fed and fasted states. The data showed differences in maximum concentration ( C max) depending on the administration condition (fed or fasted).

Long-term and Comparative Studies

Research analyzed the frequency of flare-ups as a long-term endpoint over a 12-month period. These open-label extension studies reported various outcomes. Trials included individuals with a history of heart issues to evaluate specific safety outcomes.

How should Codin P be stored and disposed of?

How to Store and Dispose of Codin P

Codin P (Chlorpheniramine Maleate) tablets must be stored at controlled room temperature, typically between 20 C and 25 C, and away from excess heat and moisture (such as in a bathroom). The product must be kept in its original container, which should be tightly closed, and also be protected from light to maintain its stability and labeled shelf life.

Child Safety and Disposal

Official labeling requires the medication to be stored out of sight and reach of children, and safety caps must always be locked. For disposal, unused or expired medicine must be taken to an authorized drug take-back location. If no program is available, the product should be mixed with an undesirable substance, sealed in a container, and disposed of in the household trash, as specified by the FDA.

Codin P